Cancer and Translational Research Lab, Dr. D. Y. Patil Biotechnology & Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra 411033, India.
Curr Cancer Drug Targets. 2019;19(3):189-198. doi: 10.2174/1568009618666180628102247.
Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create an interface with outside environment that leads to the unique identity of a specific cancer type. Among various contributors to tumor heterogeneity, cellular heterogeneity immensely plays a role in drug resistance and relapse of cancer. Within cellular heterogeneity of tumor, tumor-associated macrophages (TAMs) are the pro-tumor type of immune cells that promote growth, metastasis and drug resistance in breast carcinoma and other cancer types. Revealing the molecular aspects of TAMs can provide a breakthrough to remove therapeutics blockade to existing drugs and this understanding in future will pave the way for a new class of cancer immunotherapeutic. This review addresses current understanding of the role of TAMs in breast carcinoma hallmarks and clarifies the current scenario of pre-clinical drugs directed to tame pro-cancer TAMs.
肿瘤异质性存在于各种癌症类型中,包括乳腺癌,在肿瘤标志的表现中起着关键作用。肿瘤异质性被视为一种常见的景观,其中包括细胞和非细胞因素的肿瘤内成分与外部环境形成接口,导致特定癌症类型的独特特征。在肿瘤异质性的各种贡献者中,细胞异质性在癌症的耐药性和复发中起着重要作用。在肿瘤的细胞异质性中,肿瘤相关巨噬细胞(TAMs)是促进乳腺癌和其他癌症类型生长、转移和耐药性的促肿瘤类型免疫细胞。揭示 TAMs 的分子方面可以为消除现有药物治疗的障碍提供突破,未来的这一理解将为一类新的癌症免疫治疗铺平道路。本综述探讨了 TAMs 在乳腺癌标志中的作用的现有认识,并阐明了针对驯服促癌 TAMs 的临床前药物的现状。